Vivoryon Therapeutics NV represents core values of innovation, collaboration, and commitment to addressing unmet medical needs. The company is dedicated to developing innovative small molecule therapeutics for challenging diseases, particularly in the field of age-related diseases. By fostering strong collaborations and partnerships, Vivoryon Therapeutics aims to accelerate the discovery and development of groundbreaking treatments. With a focus on precision medicine, the company seeks to improve patient outcomes and quality of life. Vivoryon Therapeutics NV is committed to advancing scientific knowledge and delivering effective therapies to patients worldwide.

Vivoryon Therapeutics NV is primarily present in Europe, specifically in Germany and the Netherlands.

Vivoryon Therapeutics NV has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising funds to further advance its innovative therapeutic programs. Vivoryon also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, QSI-001, a potential treatment for Alzheimer's disease. Moreover, Vivoryon has initiated multiple clinical trials, including Phase 1b/2a studies for QSI-001, demonstrating its commitment to advancing novel therapies for serious diseases. These milestones highlight Vivoryon Therapeutics NV's progress in developing transformative treatments and underline its dedication to improving patients' lives.

Vivoryon Therapeutics NV is a biotech company that specializes in developing small molecule therapeutics for the treatment of neurodegenerative diseases. Founded in 2017, Vivoryon Therapeutics NV is based in Germany and focuses on targeting the ubiquitin-proteasome system and the unfolded protein response to tackle diseases like Alzheimer's and Parkinson's. The company's innovative platform has attracted numerous partnerships and collaborations with renowned academic institutions and pharmaceutical companies. With a strong commitment to research and development, Vivoryon Therapeutics NV aims to improve patients' lives by advancing novel therapies for neurodegenerative disorders.

The main competitors of Vivoryon Therapeutics NV in the market are other pharmaceutical and biotechnology companies that specialize in developing therapeutics for various diseases and conditions. These competitors include large multinational corporations as well as smaller research-focused organizations. It is important for Vivoryon Therapeutics NV to stay competitive in the market by continuously innovating and developing their drug candidates to address unmet medical needs.

Vivoryon Therapeutics NV is primarily active in the healthcare and biotechnology industries.

The business model of Vivoryon Therapeutics NV is focused on developing small molecule drugs for treating age-related diseases. Vivoryon Therapeutics NV utilizes a unique approach called "drug surveillance technology" to identify specific enzymes involved in aging processes and develop novel drugs to target them. By targeting enzymes implicated in diseases like Alzheimer's and Parkinson's, Vivoryon Therapeutics NV aims to modify disease progression and improve patient outcomes. Through strategic partnerships, collaborations, and clinical trials, the company aims to bring innovative therapies to market and revolutionize the treatment landscape for age-related diseases.

De K/W-verhouding kan momenteel niet worden berekend voor Vivoryon Therapeutics.

De KUV kan momenteel niet worden berekend voor Vivoryon Therapeutics.

De AlleAktien Kwaliteitsscore voor Vivoryon Therapeutics is 4/10.

De omzet kan momenteel niet worden berekend voor Vivoryon Therapeutics.

De verwachte Vivoryon Therapeutics winst is -18,43 mln. EUR.

Vivoryon Therapeutics NV is a company specializing in the development of therapeutics for the treatment of age-related diseases. The company uses the latest technologies and research findings to discover and develop innovative compounds that can effectively combat age-related diseases. The business model of Vivoryon Therapeutics is based on the development and commercialization of drugs for the treatment of Alzheimer's disease, Parkinson's disease, ALS, and other age-related disorders. The company follows a rational drug discovery approach that focuses on the identification of molecules that specifically interact with disease processes. An important pillar of Vivoryon Therapeutics' business model is collaboration with partners and customers. The company works closely with pharmaceutical and biotech companies to license or sell its technologies and products. By collaborating with existing industry players, Vivoryon Therapeutics can leverage synergies and optimize the distribution of its products. Vivoryon Therapeutics has divided its business fields into several segments, each focused on the development of different products and technologies. The main segments include: 1. Discovery of drug candidates: The company uses its proprietary "Functional Tau Pipeline Technology" platform to discover and develop drug candidates that target disease processes specifically. 2. Drug development: Vivoryon Therapeutics employs innovative screening technologies and optimizes its drug candidates to enhance the efficacy and tolerability of the medications. The company also works on the development of combination therapies and personalized medicines. 3. Commercialization: The company aims to bring its products to the global market and become a leading provider of therapeutics for the treatment of age-related diseases worldwide. Vivoryon Therapeutics follows a strategy of direct sales but also collaborates with distribution partners to bring its products to various regional markets. The business model of Vivoryon Therapeutics is based on the development of innovative therapeutics for the treatment of age-related diseases, relying on the discovery and development of drug candidates and innovative screening technologies. The company works closely with other industry players to leverage synergies and optimize the distribution of its products. Vivoryon Therapeutics follows a strategy of direct sales but also collaborates with distribution partners to bring its products to various regional markets.

Vivoryon Therapeutics keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Vivoryon Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van Vivoryon Therapeutics is NL00150002Q7.

Het WKN van Vivoryon Therapeutics is A2QJV6.

De ticker van Vivoryon Therapeutics is VVY.AS.

Binnen de laatste 12 maanden betaalde Vivoryon Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Vivoryon Therapeutics naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Vivoryon Therapeutics is momenteel .

Vivoryon Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Vivoryon Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Vivoryon Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Vivoryon Therapeutics van 3-8-2025 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 3-8-2025 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 3-8-2025.

In het jaar 2024 heeft Vivoryon Therapeutics 0 EUR aan dividenden uitgekeerd.

De dividenden van Vivoryon Therapeutics worden in EUR uitgekeerd.